维立志博康小强:顺周期突围,做差异化新药 | 36氪专访

36氪
Oct 16, 2025

在今年港股创新药企IPO浪潮中,来自江苏南京的维立志博成为一匹“黑马”。上市首日股价翻倍的表现、“TCE第一股”的名号,让这家低调运营11年的药企名噪一时,管理层抓住机会,将融资额提高一倍,成功募资了近14亿港币。维立志博,是一家肿瘤免疫治疗公司,当前有14款候选药物,其中6款进入临床试验阶段。维立志博创始人、董事长、CEO康小强告诉36氪,2026年要申报5个新药IND;公司重磅管线LBL-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10